Quick Facts

• May be used to assist with: The dissolution of certain uric acid and calcium-oxalate kidney stones and urinary tract stones.
• May be considered for: Preventing the new formation of these types of stones following initial treatment.
• Therapeutic objective: To achieve urine alkalization (increasing the urine's pH level) to support stone management.

Блемарен is indicated for use in the management of specific types of urinary stones. Its therapeutic role centers on increasing the alkalinity of the urine, which may help support the breakdown and passage of certain stones composed of uric acid. It is also considered for the purpose of prophylaxis—or follow-up care—to assist in preventing the reoccurrence or growth of both uric acid and calcium-oxalate stones within the urinary tract.

Furthermore, this medication may be utilized to achieve urine alkalization in patient protocols involving specific medications, such as certain cytostatics, or in the supportive care of individuals with cystine stones. The primary goal is to maintain a targeted urine pH range as determined by a healthcare professional, which contributes to the management of stone formation. For detailed information on the drug's approved uses and administration, patients should refer to professional medical guidance and product information.

This medication is a component of a comprehensive treatment plan and is intended to be used under medical supervision.

Regulatory References

1. EMA therapeutic overview

Who Can and Cannot Use Блемарен?

Eligibility for Блемарен (Potassium-Sodium Hydrocitrate) is strictly defined by regulatory documents, primarily focusing on pre-existing clinical conditions that affect the body’s ability to handle potassium and sodium.

Contraindicated Populations

This medicine must not be used by patients with:

• Severe Renal Impairment (e.g., anuria or azotemia).
• Hyperkalemia (high blood potassium) or conditions that predispose to it, such as untreated Addison's disease or severe dehydration.
• Severe Myocardial Damage or Severe Heart Failure.
• Active Urinary Tract Infection (UTI) or Peptic Ulcer Disease.

Restricted and Conditional Use

Use is established for adults for stone management. However, use requires caution and monitoring in patients with non-severe renal impairment, hepatic impairment, or cardiovascular conditions like hypertension, due to the drug’s potassium and sodium content. Safety and efficacy are not established in the pediatric population (children and adolescents). For pregnancy and lactation, use is not recommended unless the potential benefit significantly outweighs the potential risk, as data in these groups are limited or insufficient.

Блемарен's official interaction profile is primarily based on its function as a urinary alkalizer and its component salts, which influence electrolyte balance and urine pH. The documented interaction patterns define specific restrictions and requirements for co-administration with other medicinal products.

Electrolyte and Pharmacodynamic Interactions

The medicine's potassium and sodium content establishes the basis for pharmacodynamic interactions with agents that also affect potassium homeostasis. Co-administration with Potassium-sparing diuretics, ACE Inhibitors, and Angiotensin II Receptor Blockers (ARBs) may lead to an additive effect that increases the risk of hyperkalemia (elevated serum potassium levels). Furthermore, this electrolyte risk also applies to co-administration with Cardiac Glycosides, which is associated with an increased risk of systemic toxicity.

Pharmacokinetic and Administration Constraints

The mechanism of increasing urine pH results in significant alterations to renal clearance for other compounds. This effect decreases the elimination rate of weak organic bases, potentially increasing their systemic exposure, while simultaneously increasing the elimination rate for weak organic acids, which may reduce their exposure. Due to the risk of increased systemic aluminum absorption, aluminum-based antacids must not be administered concurrently. Co-administration with Licorice is associated with an increased risk of specific side effects. The overall risk of interaction complications, such as systemic alkalosis, is amplified in patients with impaired renal function, necessitating mandated monitoring of serum electrolytes.

Metabolic Alkalization and Urinary pH Modulation

The mechanism begins systemically, as the ingested citrate salts are absorbed and metabolized by the body's cells, generating a net alkali load ( HCO3^-). This metabolic activity obligates the renal system to excrete the base, which directly elevates the urine's hydrogen potential (pH), resulting in a sustained alkaline urine pH.

Litholytic Dissolution and Solute Control

The resultant alkaline urine drives a physiochemical shift in the urinary environment: the poorly soluble uric acid is converted into its highly soluble urate anion form. This process dramatically reduces the urinary saturation of the solute, promoting the chemical dissolution of existing crystalline formations.

Calcium Chelation and Crystallization Inhibition

The mechanism is completed by the direct action of the excreted citrate anion, which functions as a crystallization inhibitor. Citrate sequesters free ionic calcium ( Ca^2+) by forming stable complexes, thereby reducing the concentration of free calcium available for the nucleation and growth of new calcium-based crystals within the urinary tract.

Administration Protocol

The standard administration protocol for Блемарен involves its use exclusively via the oral route, prepared as a solution from effervescent tablets. The general usage is designed around a precision monitoring system rather than a fixed regimen.

Dosage and Schedule

The standard adult daily dose range is 2 to 6 tablets, which must be administered in three equally divided parts throughout the day. This dosage is not fixed but operates on a titration regimen, where the dose is adjusted individually based on the measured pH of the patient's urine. The prepared solution is consistently administered after meals.

Preparation and Monitoring

Proper use requires that the effervescent tablet be fully dissolved in approximately 200 mL of liquid (such as water or tea) before ingestion. Efficacy control is achieved through frequent urine pH determination, which must be performed three times daily immediately before each scheduled dose. The goal is to maintain the urine within a specific target range, such as 7.0–7.2 for dissolution purposes. If the measured pH is below the target, the next dose is adjusted upward; if it is above the range, the dose is adjusted downward.

Contextual Constraints

The protocol includes specific contextual constraints: patients must ensure adequate daily fluid intake (typically not less than 1.5–2 L). Furthermore, a time separation of at least two hours is required between the administration of this product and any preparations that contain aluminum. Use in individuals with chronic renal failure is permitted only if the condition is not accompanied by potassium ion retention.

Recent Clinical Evidence

Overview of Clinical Research

Studies have been conducted to understand the drug's properties, which involve the alkalization of urine through the action of citrate and bicarbonate salts. Initial Phase 1 and 2 trials primarily focused on collecting safety data and determining the dose range. Later-stage research has explored whether the combination of therapies may be associated with improved mobility and quality of life, particularly in patients with urolithiasis.

Key Efficacy Findings

Clinical research has focused on the use of the drug for the dissolution of kidney stones. Evidence from randomized controlled trials (RCTs) provided data indicating that the stone's characteristics, such as low density (e.g., less than 500 Hounsfield units) and small size (e.g., less than 10 mm), are critical factors associated with the success of litholytic therapy.

Studies examining patients with stones of low density and small size provided data suggesting a high probability of successful dissolution, often within one to three months, provided urine pH is maintained within the targeted range (typically 6.2–7.4). One study provided data indicating a lower frequency of stone-related events for the treatment group compared to the placebo group.

Safety and Tolerability Data

Safety data collected from most adult patients studied described the drug's tolerability profile. The most frequently reported adverse events in clinical trials were related to the gastrointestinal tract, including reports of mild nausea, abdominal pain, and diarrhea. These events are typically managed by adjusting the administration schedule or dosage. Clinical data includes information regarding use by people with specific conditions, such as liver impairment, with safety observations reported across various patient subgroups.

Key Studies & References

1. The role of urinary alkalinization in the treatment of calcium oxalate urolithiasis: a randomized study

Common questions about Блемарен (FAQ)

Q: Do users need to be concerned about an allergic reaction to Блемарен?

Official safety documents, such as the Summary of Product Characteristics (SmPC), generally list hypersensitivity (an allergic reaction) to the medicine's active components or excipients as a contraindication, meaning use is restricted for individuals with known sensitivity. Allergic reactions may also be listed as a potential undesirable effect listed in regulatory documents.

---

Q: Does Блемарен make people feel unusually tired or fatigued?

The official list of potential undesirable effects, sourced from clinical trials and safety surveillance, may include general symptoms like fatigue or tiredness. This type of event is typically categorized by regulatory documents under systemic or nervous system disorders.

---

Q: Can taking Блемарен lead to changes in body weight?

Information regarding adverse events in official drug labels sometimes reports changes in body weight. This type of effect is usually found under the Metabolic and Nutritional System-Organ Class of disorders, along with potential disturbances in appetite.

---

Q: Is a metallic taste in the mouth sometimes reported by users of Блемарен?

The official safety profile sometimes reports dysgeusia (a disturbance of the sense of taste, which can include a metallic taste) as an undesirable effect. This is listed as a potential undesirable effect under the Gastrointestinal or Nervous System classification.

---

Q: What happens if I forget to take a dose of Блемарен?

Official drug instructions typically address what to do when a dose is missed. Official drug instructions for a missed dose often describe a protocol where the user skips the forgotten dose and continues with the next dose at the regular time, without double-dosing.

---

Q: Is Блемарен appropriate for use by people who also have diabetes?

Regulatory documents often include a specific caution or special warning regarding the use of this medicine in patients with diabetes mellitus. These warnings usually describe the need for careful monitoring due to potential risks related to glucose metabolism.

---

Q: Can Блемарен be taken with common over-the-counter pain relievers like ibuprofen or paracetamol?

The official interaction profile indicates that this medicine's action of changing urine pH can alter the body's elimination rate for other compounds, including certain weak acids and bases. This potential change in elimination is why the regulatory documents require review for specific warnings regarding co-administration with common pain relievers, such as NSAIDs like ibuprofen or paracetamol.

---

Q: Is it normal to notice a change in the way my urine smells when taking Блемарен?

The official list of documented undesirable effects may include a change in urine odor as a reported event. This information is derived from post-marketing reports and clinical safety data and is often listed under urinary system disorders.

How to Store and Dispose of Блемарен?

The official storage and disposal requirements for Блемарен are set by regulatory health authorities and focus on maintaining the stability of the effervescent tablets while ensuring safety and environmental protection.

---

️ Official Storage Conditions

Requirement	Instruction
Temperature	Store the medicinal product below 30°C.
Container Integrity	The container must be kept tightly closed to protect the hygroscopic tablets from moisture.
Restrictions	Do not refrigerate or freeze. Store in the original package.
Child Safety	Keep out of the sight and reach of children.

---

️ Disposal Requirements

• Unused Product: Dispose of any unused or expired medicinal product in accordance with local regulatory requirements.
• Environmental Protection: The product must not be disposed of via wastewater or household waste to minimize environmental release.